Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.

ABSTRACT: Antibodies against coronavirus spike protein potently protect against infection and disease, but whether such protection can be extended to variant coronaviruses is unclear. This is exemplified by a set of iconic and well-characterized monoclonal antibodies developed after the 2003 SARS outbreak, including mAbs m396, CR3022, CR3014 and 80R, which potently neutralize SARS-CoV-1, but not SARS-CoV-2. Here, we explore antibody engineering strategies to change and broaden their specificity, enabling nanomolar binding and potent neutralization of SARS-CoV-2. Intriguingly, while many of the matured clones maintained specificity of the parental antibody, new specificities were also observed, which was further confirmed by X-ray crystallography and cryo-electron microscopy, indicating that a limite

SUBMITTER: Rouet R 

PROVIDER: S-EPMC8158043 | biostudies-literature | 2021 Jan-Dec

REPOSITORIES: biostudies-literature